(Q38564926)

4 September 2017

1 reference

title

Defining and treating high-risk multiple myeloma (English)

1 reference

4 September 2017

S Z Usmani

1

1 reference

4 September 2017

P Rodriguez-Otero

2

1 reference

4 September 2017

M Bhutani

3

1 reference

4 September 2017

M-V Mateos

4

1 reference

4 September 2017

J S Miguel

5

1 reference

4 September 2017

publication date

12 August 2015

1 reference

4 September 2017

1 reference

4 September 2017

volume

29

1 reference

4 September 2017

issue

11

1 reference

4 September 2017

page(s)

2119-2125

1 reference

Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group

4 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.209

Autologous stem cell transplantation in multiple myeloma patients <60 vs >/=60 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.209

Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.209

Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.209

International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.209

A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.209

Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.209

Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.209

Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.209

Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.209

Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.209

Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.209

Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.209

Prognostic significance of copy-number alterations in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.209

IMWG consensus on risk stratification in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.209

A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.209

International staging system for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.209

Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.209

Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-r

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.209

A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.209

A gene expression signature for high-risk multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.209

Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.209

Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with Total Therapy protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.209

High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.209

Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.209

Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.209

Clinical and biologic implications of recurrent genomic aberrations in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.209

Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.209

A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.209

Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.209

Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.209

Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.209

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.209

Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.209

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.209

Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myélome experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.209

Heterogeneity of outcome with single-agent carfilzomib: all relapsed/refractory myelomas are not created equal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.209

TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.209

Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.209

Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.209

Impact of genetic abnormalities after allogeneic stem cell transplantation in multiple myeloma: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.209

Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.209

Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.209

Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.209

Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.209

Prediction of Survival in Multiple Myeloma Based on Gene Expression Profiles Reveals Cell Cycle and Chromosomal Instability Signatures in High-Risk Patients and Hyperdiploid Signatures in Low-Risk Patients: A Study of the Intergroupe Francophone du M

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.209

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.209

Hypodiploidy is a major prognostic factor in multiple myeloma

21 January 2018

1 reference

12 December 2020

Prognostic implications of DNA aneuploidy in 156 untreated multiple myeloma patients. Castelano-Leonés (Spain) Cooperative Group for the Study of Monoclonal Gammopathies

1 reference

12 December 2020

Age is not a prognostic variable with autotransplants for multiple myeloma

1 reference

12 December 2020

Genetic Abnormalities and Patterns of Antigenic Expression in Multiple Myeloma

1 reference

12 December 2020

High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma

1 reference

12 December 2020

The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis

1 reference

12 December 2020

Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated

1 reference

12 December 2020

Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study

1 reference

12 December 2020

Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p

1 reference

12 December 2020

Identifiers

DOI

10.1038/LEU.2015.209

1 reference

Dimensions Publication ID

4 September 2017

1018475875

0 references

Fatcat ID

release_3evm4e55ebgxncay4gsu4wpvbq

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/3evm4e55ebgxncay4gsu4wpvbq

24 November 2022

mapped directly with Wikidata item

1 reference